Union Hospital of Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, 430000, China
NCT Number: NCT06475066
In order to explain the value of adding CESM into the clinical pathway, and also to obtain the relevant clinical data to support future update of clinical guideline, we plan to evaluate the detection rate of CESM for additional findings on preoperative breast MRI and the relevant clinical safety in the study.
Trial opening soon.
Get Notified18 year–75 year
Female
Interventional
Not applicable
Wuhan, Hubei, 430000, China
The goal of the prospective, multicenter, interventional Study is to prospectively evaluate the detection rate of preoperative contrast enhanced spectral mammography for additional suspicious findings of preoperative breast MRI in patients presenting with index breast lesions (BI-RADS ≥ 4).
The study plans to include 320 adult female patients with Index lesions of "BI-RADS≥4" in breast MRI.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
After enrollment, subjects should undergo contrast-enhanced spectral mammography again within within 28 days of MRI examination.
Iopromide/contrast agent is intravenously administered two minutes prior to the first (dual-energy) image acquisition.
Other names: CEM, CESM
Time frame: within 28 days of MRI examination
The detection rate of preoperative contrast-enhanced spectral mammography in 28 days after breast MRI for the detection of additional MRI findings in patients with breast index lesions (BI-RADS ≥ 4).
The efficacy analysis data set of the study included all subjects who have obtained breast MRI and CESM with adequate image quality (score ≥ 2 of the 1-5 rating scale).
Time frame: within 28 days of MRI examination
Time frame: within 28 days of MRI examination
Time frame: within 28 days of MRI examination
Time frame: within 28 days of MRI examination
Time frame: within 28 days of MRI examination
Score 1: insufficient image quality and cannot meet the diagnostic requirements Score 2: the image quality is average and basically meets the diagnostic requirements Score 3: The image quality is good and meets the diagnostic requirements Score 4: The image quality is good and meets the diagnostic requirements Score 5: The image quality is excellent and meets the diagnostic requirements
Time frame: During imaging procedure, 1 hour
Percentage of ADR in 1 hour post Iopromide administration
Time frame: During imaging procedure, 1 hour
Average gland dose (AGD) of CESM
Contact information is provided by the study sponsor or research team.
Fan Yang, Dr.
CONTACT
Juan Tao, Dr.
CONTACT
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Other
Clinical Effectiveness of cOntrast Enhanced Mammography in Diagnosis of Additional Findings at Preoperative Breast Magnetic ResOnance Imaging: A Prospective, Multicenter, Interventional Study
Acronym: COMBO-I
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07619534
Breast Cancer, Breast Carcinoma
Bethesda, Maryland, United States
View Trial DetailsNCT07753226
Breast Cancer, Breast Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT07752875
Adnexal Diseases, Breast Cancer
View Trial DetailsNCT07752238
Breast Cancer, Breast Diseases
View Trial Details